Better Health for All

Seres Therapeutics' core business is developing microbiome therapeutics, with VOWST being their first FDA-approved product for preventing recurrent *C. difficile* infection (CDI), an Urgent Health Threat.

Their entire portfolio is dedicated to addressing serious diseases, indicating a revolutionary health benefit focus. VOWST was approved in April 2023 , and there is no evidence of harmful products or revenue from them. The company provides comprehensive risk disclosures for VOWST, including potential transmission of infectious agents, allergens, and common adverse reactions, along with clear reporting mechanisms to Aimmune Therapeutics and the FDA. However, the high list price of $17,500 for VOWST is identified as a major risk potentially limiting accessibility, which impacts risk transparency. Seres is pioneering a new modality of microbiota-based therapeutics and has an active clinical development program, including SER-155 which received FDA Breakthrough Therapy and Fast Track designations , demonstrating revolutionary innovation. The company has a Seres Scholars program to promote equity in education for underserved students , but this is not a health equity program as defined by the rubric. VOWST is indicated to prevent the recurrence of CDI , and SER-155 is designed to prevent bacterial bloodstream and antimicrobial resistant infections , showing a transformative focus on disease prevention. Seres partners with CARB-X, a global non-profit accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death , demonstrating significant contributions to global health crisis response. The company conducts placebo-controlled Phase 1b and Phase 3 clinical trials (ECOSPOR III and IV) and has an Expanded Access Program , indicating strong ethical frameworks for clinical trials.

Fair Money & Economic Opportunity

Seres Therapeutics is a biotechnology company focused on developing microbiome therapeutics,

not a financial institution. Its core business involves developing and selling pharmaceutical products like VOWST. As such, the company does not offer lending or deposit services, consumer credit products, or manage customer financial data. Therefore, all KPIs related to financial services, such as underserved client share (in the context of lending/deposit services), pricing fairness (APRs), exploitative fee exposure, inclusion initiatives (loan/insurance book), data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment (in community finance), financial literacy initiatives, debt burden ratio, geographic inclusion (financial service access points), and product simplicity (financial products), are not applicable to its operations. The rubric's '0' tier explicitly covers these scenarios for companies whose core business lies outside finance or do not offer relevant financial products/services.

Fair Trade & Ethical Sourcing

No relevant evidence was found in the provided article to assess Seres Therapeutics, Inc. against the Fair Trade & Ethical Sourcing value.

Data extraction from the article was throttled, resulting in no available information.

Planet-Friendly Business

No specific, quantitative environmental data points were found in the provided articles for any of the Planet-Friendly Business KPIs.

The articles either explicitly stated that data was unavailable, or provided general company and industry information without specific environmental performance metrics for Seres Therapeutics, Inc.

Respect for Cultures & Communities

The provided article is about Seres Therapeutics, a biotechnology company. It details the company's leadership team, history, and mission.

However, there is *no* information relevant to MCRB.US (presumably a specific company or regulatory body) or Respect for Cultures & Communities. The article focuses entirely on the company's internal structure and accomplishments in the biotechnology field. Therefore, no quantitative data, regulatory issues, certifications, comparisons, or contradictions can be extracted related to the requested topics.

Safe & Smart Tech

Seres Therapeutics offers users strong privacy controls, enabling them to opt out of promotional communications, manage cookie consent via a Privacy Preference Center, and exercise rights to access, correct, delete, or object to personal information processing through a form or direct contact.

For regulatory compliance, the company has implemented standard contractual clauses adopted by the European Commission for transfers of personal information from the EEA to non-adequate countries. The privacy policy notes username and password as sensitive personal information, suggesting standard authentication practices without further detail on advanced security measures.

Zero Waste & Sustainable Products

No specific, concrete data points related to 'Zero Waste & Sustainable Products' for MCRB.US (Seres Therapeutics, Inc.) were found in the provided articles. refers to 'Serres' (with two 'r's) and its products (Serres Nemo, Serres Suction bags)

, which is a different entity from Seres Therapeutics, Inc. (MCRB.US). Articles , , and are about Seres Therapeutics, Inc. but do not contain information relevant to waste reduction, sustainability, or product lifecycle.